Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease

Sex: All

Ages: 5 Years – 18 Years

Phase: NA

Enrollment: 40

Sponsor: University of Alabama at Birmingham

Summary

Sickle cell disease (SCD) is associated with significant morbidity and mortality. Pain and many adverse outcomes occurring in sickle cell disease are inflammatory driven. Recent data has shown that gut dysbiosis is present in individuals with sickle cell disease. Gut dysbiosis has been linked to inflammation in certain diseases. Omega -3-fatty acids (fish oil) has been shown to improve pain outcomes in individuals with sickle cell disease, but its acceptance is variable. The aim of this study is to determine if a plant-based omega-3-fatty acids will be more acceptable and also improve outcomes in individuals with sickle cell disease

Eligibility Criteria

Inclusion Criteria:Diagnosis of sickle cell diseaseAge 5-18 years oldExclusion Criteria:Age less than 5 yearsAge > 18 years oldChronic transfusion therapyKnown pregnancy statusBreastfeeding mothers

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05758766). StuddyBuddy aggregates publicly available trial information.